Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

Ventrus Biosciences Inc. (VTUS)

Total paid for Promotions this month: $0
E-mails this Month: 1
Estimated Volume Generated: $0
Research Report on VTUS: Click to see
* The information presented is based on information for May , 2014
Merger to Create a Robust Biopharmaceutical Company (Mailing list information, including unsubscription instructions, is located at the end of this message.)   Ventrus Biosciences Inc. (VTUS)   VTUS reported that it has entered into a merger agreement with Assembly Pharmaceuticals in an all-stock transaction.   Once the merger is complete, the company will focus on the development of Assembly's novel, first-in-class small molecules ...read more
Promoter: pennyomega.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
VTUS Unknown compensation UNKNOWN
Max Profit: 1.82 % Gain at close: -19.85 %
  Monday night's alert IO reported strong 4th quarter results and the stock is up 29% on record volume. How's that for a start to my alerts? I also want to take a moment to clarify the frequency of my emails going forward. It's tough to find good opportunities on a daily basis, so from now on, I will just issue alerts when I find something worth while. That said, I may have found a company with explosive ...read more
Promoter: Stock Stars Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
VTUS Unknown compensation UNKNOWN
Max Profit: 0.62 % Gain at close: -2.47 %
  VTUS - Ventrus Biosciences, Inc. Phase III Results are Expected for 2nd Study www.GreatStockAlerts.com Recent Winners: $CYTR 2.20-6.79 an 208% increase in pps from our alert. ATHX 48% and DRRX Over 15%..   VTUS closed at $4.24 on Friday afternoon. Phase III results are due soon for their second study. First one was very successful. I think a high probability of success.   VTUS - Ventrus Biosciences, ...read more
Promoter: @PennyStockAlerts Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
VTUS Unknown compensation UNKNOWN
Max Profit: 2.09 % Gain at close: -4.88 %
    VTUS, Ventrus BioSciences, Inc.     ** VTUS reported that it has completed its acquisition of all rights and title to VEN 309 (iferanserin ointment for the topical treatment of symptomatic hemorrhoids) from the licensor, Sam Amer & Co.     The acquisition enables VTUS to reduce royalties by approximately 66% and aggregate milestone payments by approximately 50% (from $20 million to $10.5 million) compared ...read more
Promoter: penny to buck Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
VTUS No compensation UNKNOWN
Max Profit: 3.00 % Gain at close: Pending
      VTUS, Ventrus BioSciences, Inc.     ** VTUS reported that it has completed its acquisition of all rights and title to VEN 309 (iferanserin ointment for the topical treatment of symptomatic hemorrhoids) from the licensor, Sam Amer & Co.     The acquisition enables VTUS to reduce royalties by approximately 66% and aggregate milestone payments by approximately 50% (from $20 million to $10.5 million) compared ...read more
Promoter: Crweselect.com Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
VTUS No compensation UNKNOWN
Max Profit: 3.00 % Gain at close: Pending